BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2028-01
0 industry Phase 2/3 trial readout(s) and 1 FDA decision event(s). Active trials only; estimated dates often slip.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2028-01-01 (half) | PDUFA date (company-disclosed) | pending | BridgeBio Pharma, Inc. BBIO | infigratinib | PDUFA first half of 2028 - BridgeBio Pharma, Inc. (infigratinib) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.